Publications by authors named "Michael Kneba"

95Publications

Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV.

Haematologica 2019 05 4;104(5):955-962. Epub 2018 Dec 4.

Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie, Ludwig-Maximilians-Universität München, Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.206797DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518910PMC
May 2019

Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?

Mol Diagn Ther 2017 Oct;21(5):481-492

Department of Hematology, University of Schleswig-Holstein, Campus Kiel, Langer Segen 8-10, 24105, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40291-017-0277-9DOI Listing
October 2017

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial.

Eur J Haematol 2017 Mar 1;98(3):254-262. Epub 2016 Dec 1.

Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study group, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ejh.12825DOI Listing
March 2017

Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.

J Clin Oncol 2016 11;34(31):3758-3765

Gabor Kovacs, Sandra Robrecht, Anna Maria Fink, Jasmin Bahlo, Paula Cramer, Julia von Tresckow, Christian Maurer, Petra Langerbeins, Kirsten Fischer, Michael Hallek, and Barbara Eichhorst, University of Cologne and Center of Integrated Oncology Cologne/Bonn, Cologne; Matthias Ritgen, Michael Kneba, and Sebastian Böttcher, University of Schleswig-Holstein, Lubeck; Hartmut Döhner and Stephan Stilgenbauer, University of Ulm, Ulm; Wolfram Klapper, University of Kiel, Kiel; Clemens-Martin Wendtner, Klinikum Schwabing, Munich, Germany; and Günter Fingerle-Rowson, F. Hoffmann La-Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.67.1305DOI Listing
November 2016

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Blood 2016 Jan 20;127(2):208-15. Epub 2015 Oct 20.

Department I for Internal Medicine and Center of Integrated Oncology, University of Cologne, Cologne, Germany; Cluster of Excellence Cellular Stress Responses in Aging Associated Diseases, University of Cologne, Cologne, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-06-651125DOI Listing
January 2016

ALK-positive primary cutaneous T-cell-lymphoma (CTCL) with unusual clinical presentation and aggressive course.

J Cutan Pathol 2015 Nov 25;42(11):870-7. Epub 2015 Jun 25.

Department of Dermatology, University of Kiel, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.12547DOI Listing
November 2015

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

N Engl J Med 2014 Mar 8;370(12):1101-10. Epub 2014 Jan 8.

From the German CLL Study Group, Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University Hospital Cologne, Cologne (V.G., K.F., A.E., B.E., C.M.W., K.-A.K., M.H.), the Department for Geriatric Medicine and Research, St. Marien Hospital and University of Cologne, Cologne (V.G.), Institute of Medical Statistics and Epidemiology, Technical University Munich, Munich (R.B.), Klinikum Schwabing, Munich (C.M.W.), private oncology practice, Dresden (T.I.), Medical Department II, University of Schleswig-Holstein, City Hospital Kiel, Kiel (M.R., M.K.), the Department of Internal Medicine III, Ulm University, Ulm (S.S., H.D.), and Cluster of Excellence "Cellular Stress Responses in Aging-Associated Diseases" (CECAD), University of Cologne, Cologne (M.H.) - all in Germany; Penza Regional Oncology Dispensary, Penza (T.C.), and Regional Clinical Hospital N.A. Semashko, Nizhny Novgorod (O.S.) - both in Russia; Servicio De Hematologia, Hospital Universitario 12 De Octubre, Madrid (J.S.); Hôpital Haut Lévêque, Bordeaux, Pessac, France (M.-S.D.); the Department of Haematology, Monash Medical Centre, Clayton, Australia (S.O.); University of Calgary, Calgary, AB, Canada (C.J.O.); the Department of Immunology, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands (A.W.L.); F. Hoffmann-La Roche, Basel, Switzerland (E.A.); F. Hoffmann-La Roche, Welwyn, United Kingdom (K.H.); and Genentech, South San Francisco, CA (M.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1313984DOI Listing
March 2014

Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

Clin Cancer Res 2014 Feb 18;20(4):985-94. Epub 2013 Dec 18.

Authors' Affiliations: Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, and University of Tübingen; Institute of Pharmacy, Department of Pharmacology, University of Tübingen; Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen; Institute of Experimental and Clinical Pharmacology, Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel; Institute of Anatomy and Cell Biology, University of Würzburg, Würzburg, Germany; and Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1999DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932302PMC
February 2014

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV.

J Clin Oncol 2014 Feb 2;32(5):415-23. Epub 2013 Dec 2.

Rüdiger Hehlmann, Martin C. Müller, Benjamin Hanfstein, Alice Fabarius, Annette Schreiber, Ulrike Proetel, Nadine Pletsch, Susanne Saußele, Universitätsmedizin Mannheim Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim; Jolanta Dengler Universitätsklinikum Heidelberg, Heidelberg; Michael Lauseker, Markus Pfirrmann, Joerg Hasford, Institut für Medizinische Informationsverarbeitung, Biometrie und Epidemiologie (IBE), Ludwig-Maximilians-Universität; Christoph Nerl, Städtisches Klinikum Munchen Schwabing; Hans-Jochem Kolb, Klinikum rechts der Isar, Technische Universität München; Karsten Spiekermann, Universitätsklinikum, Ludwig-Maximilians Universität München; Claudia Haferlach, Susanne Schnittger, MLL Münchner Leukämielabor, Munich; Hermann Einsele, Universitätsklinikum Würzburg, Würzburg; Christiane Falge, Klinikum Nürnberg Nord, Nuremberg; Lothar Kanz, Universitätsklinikum Tübingen, Tübingen; Andreas Neubauer, Universitätsklinikum Gießen und Marburg, Marburg; Michael Kneba, Universitätsklinikum Schleswig-Holstein, Kiel; Frank Stegelmann, Hermann Heimpel, Universitätsklinikum Ulm, Ulm; Michael Pfreundschuh, Universitätsklinikum des Saarlandes, Homburg/Saar; Cornelius F. Waller, Universitätsklinikum Freiburg, Freiburg; Gerhard Ehninger, Universitätsklinikum Carl Gustav Carus, Dresden; Stefan W. Krause, Universitätsklinikum Erlangen, Erlangen; Dieter K. Hossfeld, Universitätsklinikum Eppendorf, Hamburg; Andreas Hochhaus, Universitätsklinikum Jena, Jena, Germany; Gabriela M. Baerlocher, Inselspital Bern, Bern; Dominik Heim, Universitätsspital Basel, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.9020DOI Listing
February 2014

The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?

Hematol Oncol Clin North Am 2013 Apr;27(2):267-88

Second Department of Medicine, University Hospital of Schleswig-Holstein, Kiel 24116, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2013.01.005DOI Listing
April 2013

Flow cytometric MRD detection in selected mature B-cell malignancies.

Methods Mol Biol 2013 ;971:149-74

Second Department of Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/978-1-62703-269
Web Search
http://link.springer.com/10.1007/978-1-62703-269-8_9
Publisher Site
http://dx.doi.org/10.1007/978-1-62703-269-8_9DOI Listing
June 2013

Has MRD monitoring superseded other prognostic factors in adult ALL?

Blood 2012 Nov 2;120(23):4470-81. Epub 2012 Oct 2.

Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Chemnitzstrasse 33, Kiel, Germany.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2012-06-37
Publisher Site
http://dx.doi.org/10.1182/blood-2012-06-379040DOI Listing
November 2012

Acute lymphoblastic leukemia: monitoring minimal residual disease as a therapeutic principle.

Semin Oncol 2012 Feb;39(1):47-57

Department of Hematology, University Hospital Schleswig-Holstein, Campus Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2011.11.009DOI Listing
February 2012

Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma.

Cancer 2011 May 29;117(9):1901-10. Epub 2010 Nov 29.

Department of Hematology, University of Heidelberg, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.25756DOI Listing
May 2011

[Antibody therapy in hematology and oncology--2].

Med Klin (Munich) 2009 Jan;104(1):28-49

II Medizinische Klinik und Poliklinik, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00063-009-1005-yDOI Listing
January 2009

[Antibody therapy in hematology and oncology - part 1].

Med Klin (Munich) 2008 Dec;103(12):843-59

II. Medizinische Klinik und Poliklinik, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00063-008-1133-9
Publisher Site
http://dx.doi.org/10.1007/s00063-008-1133-9DOI Listing
December 2008

[Treatment of nonresectable liver metastases].

Onkologie 2008 14;31 Suppl 5:14-8. Epub 2008 Nov 14.

I. Medizinische Klinik und Poliklinik, Universitätsklinik Mainz, Mainz, Deutschland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000163068DOI Listing
February 2009

C1qRP (CD93) expression on peripheral blood monocytes in patients with systemic lupus erythematosus.

Rheumatol Int 2006 Oct 4;26(12):1109-12. Epub 2006 May 4.

Second Medical Department, University Hospital of Schleswig Holstein, Campus Kiel, Chemnitzstr. 33, 24116 Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00296-006-0132-5DOI Listing
October 2006

Flow cytometric assay for determination of FcgammaRIIIA-158 V/F polymorphism.

J Immunol Methods 2005 Nov 8;306(1-2):128-36. Epub 2005 Sep 8.

Second Department of Medicine, University of Schleswig-Holstein, Campus Kiel, Chemnitzstrasse 33, D-24116 Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jim.2005.08.004DOI Listing
November 2005

Establishment and optimization of a flow cytometric method for evaluation of viability of CD34+ cells after cryopreservation and comparison with trypan blue exclusion staining.

Transfusion 2005 Jul;45(7):1208-13

Second Department of Medicine of the University Clinic Schleswig-Holstein Campus Kiel, Dr Mildred Scheel Haus, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1537-2995.2005.00174.xDOI Listing
July 2005

Significance of minimal residual disease in lymphoid malignancies.

Acta Haematol 2004 ;112(1-2):111-9

II. Medizinische Klinik, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000077566DOI Listing
July 2004

Risk-adapted treatment according to minimal residual disease in adult ALL.

Best Pract Res Clin Haematol 2002 Dec;15(4):639-52

J.W. Goethe University Hospital, Medical Clinic III, Theodor Stern Kai 7, 60590, Frankfurt, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/beha.2002.0229DOI Listing
December 2002